China Radioligand Therapy Market Segment Insights, Analysis and Growth
The China radioligand therapy market is expanding with new treatment approvals, domestic isotope production, and rising cancer demand. China's PSMA-targeted therapeutic radioligand market is forecast to grow from USD 402.5 million in 2026 to USD 1415.95 million by 2035, at a CAGR of 15%.
Last Updated : 07 October 2026
Category: Therapeutic Area
Insight Code: 7080
Format: PDF / PPT / Excel